During clinical trials, each bispecific antibody is meticulously studied with various administration routes, infusion times, and dosing schedules to strike a balance between maximizing therapeutic efficacy and minimizing adverse events. By carefully studying these factors in controlled clinical trial settings, scientists aim to develop treatment regimens that are not only highly effective but also convenient and well-tolerated for patients with multiple myeloma.

This is why each bispecific antibody has its own specific treatment plan. The way the medicine is given, the amount used, and how often it's given can be different for each type. Doctors need to consider these details when choosing the best treatment for a patient, making sure it fits their needs and preferences.

All currently FDA-approved bispecific antibody therapies to treat multiple myeloma (July 2024) can be administered subcutaneously through an injection under the skin, usually in the stomach area (abdomen). 

The frequency of administration depends on the type of bispecific antibody. It could be a weekly or biweekly administration, although that could change as more information is derived from real-world data. Continue reading about the administration frequency and treatment monitoring here.